

Sprout AI Inc. Provides Update Regarding the Amalgamation with TheraCann International Benchmark Corp & Updated Timeline

VANCOUVER, BRITISH COLUMBIA,
CANADA, July 31, 2023

/EINPresswire.com/ -- [Sprout AI](#) Inc.

(SAI) provides an update regarding the amalgamation process with [TheraCann International Benchmark Corp \(TIBC\)](#) to its shareholders. The previously scheduled amalgamation, originally set for July 31, 2023, will be rescheduled to November 30, 2023.



Sprout AI Logo

Current Progress and Successful Milestones:

1. Obtained majority consent from TIBC shareholders
2. Filled SAI's 2022 Full IFRS Audit with the BCSC securities commission.

Ongoing Tasks Regarding the Amalgamation:

1. TIBC's auditor is working on completing TIBC's Full IFRS amalgamated financial statements, excluding SAI's financial statements, to ensure accurate and transparent reporting.
2. The new date for completion will impact SAI shareholders' review of TIBC's Circular.
3. This TIBC Circular will be presented to Sprout AI's investors for approval following the completion of that Audit of TIBC.

Ongoing Business Operations:

Both companies continue to operate as usual, actively seeking new clients, expansion measures, and technology improvements with the shared objective of creating shareholder value. Prior to the Amalgamation, they will jointly provide a consolidated business update and launch an awareness campaign to enhance TheraCann Beyond Farmings' global recognition.

Trading in Sprout Shares:

Trading in Sprout Shares may continue to be temporarily affected pending confirmation of the new date for the shareholder meeting and the review of the proposed Transaction by the CSE.

About TheraCann

TheraCann is a global provider of turnkey cultivation and technology solutions. With a focus on

compliance, quality, and consistency, TheraCann's comprehensive suite of products and services supports agricultural companies throughout the entire cultivation lifecycle. TheraCann is dedicated to advancing the vertical farming industry through progressive technology and industry expertise.

About Sprout AI

Sprout AI is a technology company in the business of planning, designing, manufacturing and/or assembling scalable AI-controlled vertical cultivation equipment for international urban farming. The adaptive technology produces an environment with improved growing parameters and early detection of adverse conditions resulting in consistent and repeatable crops, with shorter cultivation cycles, independent of geographic climates. The self-contained multi-level rolling rack technology increases the cubic cultivation area while mitigating the risk of outside and cross-contaminants.

For more information about Sprout AI, please visit our website: <http://sproutai.solutions>

Chris Bolton

Chief Executive Officer

Phone: +011 (507) 320-5092

E-mail: mainweb@sproutai.solutions

Colleen McKay

Investor Relations Contact

Phone: (289) 231-9026

E-mail: cmkay@sproutai.solutions

Address: International Business Park, Unit 5B, Building 3860 Panama Pacifico, Republic of Panama

Neither the Canadian Securities Exchange nor any Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, this news release contains forward-looking statements and information relating to the completion of the Consolidation, the completion of the Transaction, the holding and the timing of the Sprout AI shareholders meeting, the Company's intention to seek Minority Shareholder Approval, the expectation that the outstanding convertible debentures of TheraCann will convert to TheraCann Shares and TheraCann's intention to distribute the Related Sprout Shares to the TheraCann Shareholders, in each case, prior to completion of the Transaction, the conditions to completing the Transaction, the completion of the TheraCann Debenture Conversion, the anticipated number of post-

Consolidation Sprout Shares to be issued as consideration for the acquisition of the TheraCann Shares, the anticipated number of post-Consolidation Sprout Shares to be outstanding at closing, the anticipated number of common share purchase warrants to be outstanding at closing, the receipt of regulatory, shareholder and exchange approvals, future plans and business objectives of the Resulting Issuer, the expected benefits of the Transaction, the expectation that that the Resulting Issuer will have access to TheraCann's extensive network, technology solutions, and resources and the resulting benefits, the intention that the Resulting Issuer will deploy a new research and development division and the related goals, the intention for the Resulting Issuer to further expand its vertical farming operations, focus on strengthening customer relationships, capture new market segments, and expand its reach through strategic partnerships and alliances.

The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company including, without limitation: that all conditions required for the Transaction will be fulfilled, that the Company will be able to obtain receipt of all shareholder, regulatory and third party approvals required for the Transaction, that TheraCann will receive all consents required to complete the TheraCann Debenture Conversion as anticipated, that the Company will issue the anticipated number of securities as consideration for the TheraCann Shares, that the number of issued and outstanding securities of the Resulting Issuer will be as currently anticipated by the parties, that COVID-19 will not materially impact the consummation of the Transaction or the businesses or personnel of Sprout AI and TheraCann, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed on reasonable terms, that the parties will be able to successfully combine their respective businesses and leverage their synergies, that the Transaction will have the expected benefits, and that the Resulting Issuer will be able to grow and improve its operations and performance as expected. As a result, there can be no assurance that the proposed Transaction or related matters will be completed as proposed or at all. Although the management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks.

These include, but are not limited to:

- there is no assurance that Sprout AI and TheraCann will obtain all requisite approvals for the Transaction, including the approval of the shareholders of Sprout AI, or the approval of the CSE

for the Transaction (which may be conditional upon amendments to the terms of the Transaction);

- following the completion of the Transaction, the Resulting Issuer may require additional financing from time to time in order to continue its operations. Financing may not be available when needed or on terms and conditions acceptable to the Resulting Issuer;
- TheraCann may not obtain all required consents to complete the TheraCann Debenture Conversion, as anticipated or at all;
- there may be unanticipated changes in the capitalization of Sprout AI or TheraCann which impact the number of securities that will be issued by Sprout AI as consideration for the TheraCann Shares and the number of securities that will be issued and outstanding at the closing of the Transaction;
- COVID-19 could cause material delays in the consummation of the Transaction;
- unanticipated costs and expenses;
- new laws or regulations could adversely affect the Resulting Issuer's business and results of operations;
- the stock markets have experienced volatility that often has been unrelated to the performance of companies. These fluctuations may adversely affect the price of the Resulting Issuer's securities, regardless of its operating performance;
- the loss of key personnel;
- the failure of the parties to successfully combine their respective businesses and benefit from the Transaction as anticipated;
- the Resulting Issuer's failure to raise further capital upon terms acceptable to the Resulting Issuer or at all; and
- the Company's failure to continue operations if the Transaction is not completed.

Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

Colleen McKay

Sprout AI Inc., Sprout AI S.A.,

+1 289-231-9026

email us here

Visit us on social media:

Facebook

Twitter

LinkedIn

Instagram

Colleen McKay

Sprout AI Inc., Sprout AI S.A.,

+ +1 2892319026

[email us here](#)

Visit us on social media:

[Facebook](#)

[LinkedIn](#)

[Instagram](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/647343802>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.